A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.
作者信息
Short Nicholas J, Kantarjian Hagop, Jabbour Elias, Cortes Jorge E, Thomas Deborah A, Rytting Michael E, Daver Naval, Alvarado Yesid, Konopleva Marina, Kebriaei Partow, Wierda William G, DiNardo Courtney D, Bivins Carol, McCue Deborah, Richie Mary A, Ravandi Farhad
机构信息
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Br J Haematol. 2018 Aug;182(3):442-444. doi: 10.1111/bjh.14806. Epub 2017 Jun 14.
Abstract
摘要
相似文献
1
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.一项针对复发或难治性B细胞急性淋巴细胞白血病成人患者的莫克妥木单抗帕苏妥昔的I期研究。
Br J Haematol. 2018 Aug;182(3):442-444. doi: 10.1111/bjh.14806. Epub 2017 Jun 14.
2
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.抗CD22免疫毒素莫克妥昔单抗帕苏妥昔用于儿童急性淋巴细胞白血病的1期研究。
Blood. 2017 Oct 5;130(14):1620-1627. doi: 10.1182/blood-2017-02-749101. Epub 2017 Aug 9.
3
Moxetumomab Pasudotox: First Global Approval.注射用米托蒽醌单抗：全球首次获批
Drugs. 2018 Nov;78(16):1763-1767. doi: 10.1007/s40265-018-1000-9.
4
Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia.抗CD22靶向疗法——莫西妥莫单抗帕苏妥昔治疗B细胞前体急性淋巴细胞白血病的特性研究
Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26604. Epub 2017 Apr 27.
5
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.抗体融合蛋白：抗 CD22 重组免疫毒素 moxetumomab pasudotox。
Clin Cancer Res. 2011 Oct 15;17(20):6398-405. doi: 10.1158/1078-0432.CCR-11-0487.
6
Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations.用于复发/难治性毛细胞白血病的莫昔妥单抗帕苏妥昔单抗-tdfk：临床考虑的综述。
Cancer Chemother Pharmacol. 2019 Aug;84(2):255-263. doi: 10.1007/s00280-019-03875-6. Epub 2019 May 27.
7
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.在既往多次治疗的复发/难治性毛细胞白血病（HCL）患者中，给予莫昔妥珠单抗帕司努他（moxetumomab pasudotox）治疗：关键性试验的长期随访结果。
J Hematol Oncol. 2021 Feb 24;14(1):35. doi: 10.1186/s13045-020-01004-y.
8
Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.一项评估抗 CD22 免疫毒素 moxetumomab pasudotox 治疗复发/难治性儿童 B 系急性淋巴细胞白血病的国际 2 期研究结果。
Pediatr Blood Cancer. 2020 May;67(5):e28112. doi: 10.1002/pbc.28112. Epub 2020 Jan 15.
9
Moxetumomab pasudotox: A first-in-class treatment for hairy cell leukemia.莫西妥莫单抗帕苏妥昔：毛细胞白血病的首款一流疗法。
J Oncol Pharm Pract. 2019 Sep;25(6):1467-1472. doi: 10.1177/1078155219838041. Epub 2019 Mar 27.
10
Moxetumomab pasudotox for the treatment of hairy cell leukemia.用于治疗毛细胞白血病的莫昔妥珠单抗。
Expert Opin Biol Ther. 2019 Jun;19(6):501-508. doi: 10.1080/14712598.2019.1614558. Epub 2019 May 10.
引用本文的文献
1
Antibody-Based and Other Novel Agents in Adult B-Cell Acute Lymphoblastic Leukemia.成人B细胞急性淋巴细胞白血病中基于抗体的及其他新型药物
Cancers (Basel). 2025 Feb 25;17(5):779. doi: 10.3390/cancers17050779.
2
Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis.临床试验中抗体药物偶联物的治疗相关不良事件：一项系统评价和荟萃分析。
Cancer Innov. 2023 Oct 15;2(5):346-375. doi: 10.1002/cai2.97. eCollection 2023 Oct.
3
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.血液系统恶性肿瘤的免疫治疗：成就、挑战与未来前景。
Signal Transduct Target Ther. 2023 Aug 18;8(1):306. doi: 10.1038/s41392-023-01521-5.
4
Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next?治疗B细胞恶性肿瘤新型药物的现状：接下来会有什么进展？
Cancers (Basel). 2022 Dec 7;14(24):6026. doi: 10.3390/cancers14246026.
5
Targeted Therapy in Acute Lymphoblastic Leukaemia.急性淋巴细胞白血病的靶向治疗
J Pers Med. 2021 Jul 25;11(8):715. doi: 10.3390/jpm11080715.
6
Targeting CD22 for the Treatment of B-Cell Malignancies.靶向CD22治疗B细胞恶性肿瘤。
Immunotargets Ther. 2021 Jul 6;10:225-236. doi: 10.2147/ITT.S288546. eCollection 2021.
7
Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple Myeloma.关于多发性骨髓瘤近期治疗成功及未来挑战的生物学和转化研究思考。
Cold Spring Harb Perspect Med. 2021 Jul 1;11(7):a034900. doi: 10.1101/cshperspect.a034900.
8
Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia.成人急性淋巴细胞白血病基于新型单克隆抗体的治疗策略
Ther Adv Hematol. 2019 May 19;10:2040620719849496. doi: 10.1177/2040620719849496. eCollection 2019.
9
Domain II of Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia.外毒素结构域 II 对急性淋巴细胞白血病异种移植模型中推注剂量的疗效至关重要。
Toxins (Basel). 2018 May 21;10(5):210. doi: 10.3390/toxins10050210.
10
Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.抗体药物偶联物治疗血液系统恶性肿瘤：全面综述。
Target Oncol. 2018 Jun;13(3):287-308. doi: 10.1007/s11523-018-0558-1.
本文引用的文献
1
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.奥英妥珠单抗对比标准疗法治疗急性淋巴细胞白血病
N Engl J Med. 2016 Aug 25;375(8):740-53. doi: 10.1056/NEJMoa1509277. Epub 2016 Jun 12.
2
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.抗 CD22 重组免疫毒素 moxetumomab pasudotox（CAT-8015 或 HA22）治疗毛细胞白血病患者的 I 期临床试验。
J Clin Oncol. 2012 May 20;30(15):1822-8. doi: 10.1200/JCO.2011.38.1756. Epub 2012 Feb 21.
3
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.抗体融合蛋白：抗 CD22 重组免疫毒素 moxetumomab pasudotox。
Clin Cancer Res. 2011 Oct 15;17(20):6398-405. doi: 10.1158/1078-0432.CCR-11-0487.
4
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.去除 B 细胞表位的抗 B 细胞恶性肿瘤重组免疫毒素在小鼠中无免疫原性。
Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5742-7. doi: 10.1073/pnas.1102746108. Epub 2011 Mar 21.
5
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.一种抗CD22的蛋白酶抗性免疫毒素，对慢性淋巴细胞白血病的活性大大增强，且动物毒性降低。
Blood. 2009 Apr 16;113(16):3792-800. doi: 10.1182/blood-2008-08-173195. Epub 2008 Nov 6.
6
Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.抗CD19和抗CD22免疫毒素在细胞内的内化差异导致不同的细胞毒性活性。
Cancer Res. 2008 Aug 1;68(15):6300-5. doi: 10.1158/0008-5472.CAN-08-0461.
Zotero 插件